Intercell: Vaccine Development to Suspend

Business › n.a. ♦ Published: April 11, 2011; 12:19 ♦ (Vindobona)

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710. The share of Intercell crashed seriously.

Intercell: Vaccine Development to Suspend / Picture: © Intercell

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment.

Although…

or Log In

Fast News Search
Related News
Intercell Announces next Steps of Development for Pseudomonas Vaccine (April 1, 2011)
Massive Losses for Intercell (March 1, 2011)
Intercell Issues Convertible Bond (February 23, 2011)
Intercell Raises Authorized Capital (December 16, 2010)
Serious setback for Intercell (December 14, 2010)
Read More
Intercell, Health Policy, Pharmaceutical Industry, Medicine
Featured
Weekly Briefing: Return to Normality in July
See latest Vindobona Newsletter